Osivax has reported phase 2b results for OVX836 and outlined the next stage of development for its next-generation seasonal ...

Merz Therapeutics has completed patient recruitment in two global phase 3 trials evaluating XEOMIN (incobotulinumtoxinA) for ...

Johnson & Johnson has announced that the CHMP recommends approval of an indication extension for TALVEY (talquetamab) plus ...

Galderma has announced new NEMLUVIO data to be presented at Fall Clinical 2026, including a post‑hoc analysis from the ...

Bespak has signed an MOU with SNBL to provide immediate and exclusive global access to SNBL’s proprietary nasal dry powder ...

Lundbeck has reported results from an open‑label phase 1b trial evaluating Lu AF28996, an investigational oral prodrug of a ...

Sanofi has broken ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany. The development will introduce a new generation of insulin production to one ...

Northwest Biotherapeutics and NHS Blood and Transplant have agreed a collaboration to support production of DCVax-L, a ...

The CHMP has issued a positive opinion recommending approval of an alternative dosing schedule for Libtayo (cemiplimab) across all approved indications. The opinion supports reducing dosing frequency ...

RougeTx has launched with a $58 million series A financing to advance RTX‑001, a potential once‑daily oral treatment designed ...

Kyowa Kirin International has announced final results from the German MINT study evaluating mogamulizumab in patients with MF ...

Laverock Therapeutics has announced new in vivo programmes spanning CAR‑T and genetic medicine, expanding its therapeutic ...